Serag Eldin Ibrahim Elbehairi

The journal retracts the article “Cell Cycle Arrest in Different Cancer Cell Lines (Liver, Breast, and Colon) Induces Apoptosis under the Influence of the Chemical Content of Aeluropus lagopoides Leaf Extracts”

In this study, two series of benzimidazole derivatives were evaluated for their anticancer activity. The first series of benzimidazole–urea was achieved from the condensation of benzimidazole aniline 1 with a variety of isocyanates. The second series was elaborated from the cycloaddition reaction of benzophenone diamine with appropriate arylaldehydes. The in vitro cytotoxic and antiproliferative properties of various benzimidazole derivatives were assessed for three specific cancer cell lines: MCF‐7, HCT116, and HePG2. Particularly, the results revealed that compounds 6b and 6c exhibited excellent activity against the three cancer cell lines, MCF‐7, HePG2, and HCT‐116, with IC ₅₀ ranging from 0.3 ± 0.01 to 0.1 ± 0.02 µg/mL for MCF‐7, 0.5 ± 0.1 to 0.3 ± 0.1 µg/mL for HePG2, and 0.2 ± 0.01 to 0.06 ± 0.001 µg/mL for HCT‐116. The existence of the hydroxyl and bromine moiety at the para position, the appropriate bromine radius ( r (Br) = 1.83 Å) for derivative 6b , and the hydroxylated group ( r (O) = 1.52 Å for oxygen) for compound 6c were taken into consideration when interpreting this finding. The docking analysis demonstrates that compounds 3e, 6b, 6c , and 6e interact with key residues in the catalytic region of caspase 3, a crucial enzyme involved in apoptosis.

This review evaluates the cytotoxic potential of the Sesbania genus, with a focus on Sesbania sesban, Sesbania grandiflora, and Sesbania cannabina. These species, known for their diverse phytochemical compositions, exhibit notable cytotoxic effects that suggest their utility in natural cancer treatments. Compounds such as quercetin, kaempferol, and sesbagrandiforian A and B have been highlighted for their strong antioxidant and antiproliferative effects, further emphasizing their therapeutic potential. The genus Sesbania exhibits a wide range of in vitro and in vivo bioactivities. Extensive research on S. grandiflora has uncovered mechanisms such as the activation of caspase cascades and the induction of apoptosis, attributed to its rich content of flavonoids and alkaloids. Notably, sesbanimides derived from S. grandiflora seeds have demonstrated potent cytotoxic effects by disrupting mitochondrial function. While S. sesban and S. cannabina have been less extensively studied, early findings highlight their potential through the inhibition of key cancer pathways and the identification of bioactive compounds such as galactomannan derivatives and 2-arylbenzofurans. Notably, the galactomannan derivatives from S. sesban exhibit significant immune-modulating properties. Additionally, nanoparticles synthesized from Sesbania species, including Cadmium oxide and PEGylated silver nanoparticles, have demonstrated promising cytotoxic activity by disrupting mitosis and enhancing immune responses. While further research is warranted, the Sesbania genus offers a promising basis for the development of innovative anticancer therapies.

The current study was designed to explore the biosynthetic potential of sevadicin in Bacillus pumilus species and its interaction with bacterial drug target molecules. The non-ribosomal peptide (NRP) cluster in B. pumilus SF-4 was preliminarily confirmed using PCR-based screening, and the bioactivity of strain SF-4 culture extract was assessed against a set of human pathogenic strains. The susceptibility assay showed that strain SF-4 extract had higher inhibitory concentrations (312–375 µg/mL) than ciprofloxacin. Genome mining of B. pumilus strains (n = 22) using AntiSMASH and BAGEL identified sevadicin coding biosynthetic gene cluster only in strain SF-4, constitutes of two core biosynthetic genes, three additional biosynthetic genes, two transport-related genes, and one regulatory gene. The molecular docking of sevadicin with various putative bacterial drug targets such as dihydropteroate, muramyl ligase E, topoisomerase, penicillin-binding protein, and in vitro safety analyses were conducted with detailed ADMET screening. The results showed that sevadicin makes hydrophobic interaction with MurE (PDB ID: 1E8C and 4C13) via hydrogen bonding, suggesting bacterial growth inhibition by disrupting the cell wall synthesis pathway and exhibiting a secure biosafety profile. The stability and compactness of sevadicin/MurE complexes were assessed via molecular dynamic simulation using RMSD, RMSF, and Rg. The simulation results revealed the binding stability of sevadicin/MurE complexes and indicated that the complexes can't be easily deformed. In conclusion, the current study explored the biosynthesis of sevadicin in B. pumilus for the first time and found that sevadicin inhibits bacterial growth by inhibiting cell wall synthesis via targeting the MurE enzyme and exhibits no toxicity.

Background: Plant-derived products or extracts are widely used in folk/traditional medicine to treat several infections, ailments, or disorders. A well-known medicinal herb, Myrtus communis is an evergreen fragrant plant native to the Mediterranean region that has been used for ages in traditional medicine around the world. Materials and methods: The microplate alamarBlue assay and the well diffusion method were used to evaluate the zone of inhibition and MIC, respectively. The double-disc diffusion method was used to investigate the synergy between antibiotics and the extract. The crystal violet method was used to investigate biofilm development. The SulphoRhodamine-B assay and DNA flow cytometry were used to investigate the proliferation and subsequent distribution of cells among different phases of the cell cycle. The apoptotic and necrotic phases of the cancer cells were examined using flow cytometry in conjunction with Annexin V-FITC/PI labeling. Using the IBM SPSS statistical program, a one-way ANOVA with Tukey’s post hoc test was employed for statistical analysis. Results: The ethanolic leaf extract of M. communis showed a strong growth inhibition effect (zone of inhibition: 20.3 ± 1.1–26.3 ± 2.5 mm, MIC: 4.88–312.5 µg/mL, and MBC: 39.07–1250 μg/mL) against several rapidly growing and slow-growing mycobacterial strains in a dose-dependent manner. Damage to the cell wall of bacterial cells was determined to be the cause of the antimycobacterial action. The extract inhibited biofilm formation (MBIC of 9.7 µg/mL) and eradicated already-formed mature and ultra-mature biofilms of M. smegmatis, with MBEC values of 78 µg/mL and 156 µg/mL, respectively. Additionally, the extract exhibited potent anticancer effects against diverse cancer cell lines of the breast (MCF-7), liver (HepG2), cervix (HeLa), and colon (HCT116) (IC₅₀ for HCT116: 83 ± 2.5, HepG2: 53.3 ± 0.6, MCF-7: 41.5 ± 0.6, and HeLa: 33.3 ± 3.6) by apoptosis after arresting the cells in the G₁ phase of the cell cycle. Conclusions: These results suggest that M. communis leaf extract is a potential source of secondary metabolites that could be further developed as potential anticancer and antimycobacterial agents to treat diverse types of cancers and mycobacterial infections.